Carbonyl reductase ChKRED20 mutant for synthesis of fused ring lactone compound and application of carbonyl reductase ChKRED20 mutant

By mutation of the specific amino acid sequence of the carbonyl reductase ChKRED20, a mutant capable of efficient synthesis of fused ring lactone was designed, which solved the problem of fused ring lactone synthesis in the prior art and achieved efficient, selective and stable catalytic effects.

CN118995649APending Publication Date: 2024-11-22SICHUAN UNIV
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202410908168.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-08
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to achieve efficient and highly selective synthesis of fused ring lactone through directional evolution and modification of enzymes, and there are problems such as harsh catalytic reaction conditions and high pollution.

Method used

By mutation of specific amino acid sequences of carbonyl reductase ChKRED20, mutants such as ChKRED20-M2 and ChKRED20-M3C1 were designed. PCR technology and single-point saturation mutation technology were used to achieve efficient asymmetric synthesis and chirality of fused ring lactones. Flip.

Benefits of technology

The efficient and highly selective asymmetric synthesis of fused ring lactone is achieved, the range of substrate recognition is expanded, the harshness and pollution of reaction conditions are reduced, and the universality and stability of catalysis are improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995649A_ABST
    Figure CN118995649A_ABST
Patent Text Reader

Abstract

The invention discloses a carbonyl reductase ChKRED20 mutant for synthesis of a fused ring lactone compound and application of the carbonyl reductase ChKRED20 mutant, and belongs to the technical field of chemical biology. The carbonyl reductase ChKRED20 mutant takes an amino acid sequence of a carbonyl reductase mutant strain ChKRED20-M2 or ChKRED20-M3C1 as a starting sequence, amino acid at the 188th site and / or the 145th site is mutated, and tyrosine at the 188th site of the ChKRED20-M2 is mutated into asparagine, glycine or cysteine; or the histidine at the 145th site of the ChKRED20-M2 is mutated into the alanine, and the tyrosine at the 188th site is mutated into the serine or cysteine. According to the invention, rational design is carried out on ChKRED20 through directed evolution, the obtained mutant strain has relatively wide substrate universality, and efficient and high-selectivity asymmetric synthesis of fused ring lactone and chiral flip of fused ring lactone are realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of chemical biotechnology, and in particular to a carbonyl reductase ChKRED20 mutant for synthesizing condensed-ring lactone compounds and an application thereof. Background Art

[0002] Under the guidance of the principles of green chemistry and sustainable development, the development of new biocatalysts for the efficient and highly selective synthesis of chiral condensed-ring lactone compounds is an urgent problem. The lactone skeleton is an important structural unit that constitutes many natural compounds and high-value pharmaceutical intermediates. At present, most catalysts used for the catalytic synthesis of chiral condensed-ring lactone compounds use relatively expensive precious metal-ligand chiral catalysts, and the synthesis of chiral metal ligand catalysts is complex, and there are problems such as harsh catalytic reaction conditions and high pollution. Therefore, the development of biocatalysts with the characteristics of high conversion rate, high selectivity, low pollution, low energy consumption, and mild reaction conditions has practical application significance. At present, only a few studies have reported the use of biocatalysts for the asymmetric synthesis of condensed-ring lactones, and they are limited by the complex coenzyme circulation system, strong substrate specificity, and instability of the catalytic process. Therefore, engineering transformation based on natural enzyme proteins is of great significance in the efficient synthesis of complex compound molecules.

[0003] Protein engineering is widely used in enzyme modification to enhance stability, expand substrate recognition range, regulate reaction selectivity and other performance optimization. However, when modifying enzymes and optimizing their catalytic performance through directed evolution, the improvement of a single catalytic performance is often accompanied by a decrease in other performances, such as changing the flexible structure of the enzyme to achieve recognition of large-volume compounds, and the thermal stability and acid-base stability of the enzyme will be reduced accordingly. So far, there has been no report on the modification of enzymes through directed evolution to achieve chiral regulation of fused-ring lactones. Summary of the invention

[0004] In order to solve the above technical problems, the purpose of the present invention is to provide a carbonyl reductase ChKRED20 mutant and application for the synthesis of fused-ring lactone compounds, so as to solve the problem of the existing lack of enzyme modification through directed evolution to achieve efficient and highly selective synthesis of chiral fused-ring lactone compounds.

[0005] The technical solution of the present invention to solve the above technical problems is as follows:

[0006] A carbonyl reductase ChKRED20 mutant for the synthesis of condensed-ring lactone compounds, wherein the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 or ChKRED20-M3C1 is used as a starting sequence, and the amino acid at position 188 and / or position 145 is mutated;

[0007] Among them, the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 was used as the starting sequence, and the tyrosine at position 188 was mutated to asparagine;

[0008] Using the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 as the starting sequence, the tyrosine at position 188 was mutated to glycine;

[0009] Using the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 as the starting sequence, the tyrosine at position 188 was mutated to cysteine;

[0010] Taking the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 as the starting sequence, the tyrosine at position 188 is mutated to serine, and the histidine at position 145 is mutated to alanine; or taking the amino acid sequence of ChKRED20-M3C1 as the starting sequence, the histidine at position 145 is mutated to alanine;

[0011] Taking the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 as the starting sequence, the tyrosine at position 188 was mutated to cysteine, and the histidine at position 145 was mutated to alanine.

[0012] The beneficial effects of the present invention are as follows: the present invention utilizes PCR technology, single-point saturation mutagenesis and site-directed mutagenesis technology to molecularly transform a mutant M2 of a carbonyl reductase ChKRED20 derived from Chryseobacterium sp. CA49, and obtains several carbonyl reductase ChKRED20 mutants capable of efficiently asymmetric synthesis of chiral tri-fused-ring lactones, and in further mutation design, obtains a carbonyl reductase ChKRED20 mutant capable of flipping the configuration of the tri-fused-ring lactone, thereby realizing efficient and highly selective asymmetric synthesis of large-volume fused-ring lactones and realizing the chirality flipping of fused-ring lactones.

[0013] Application of the carbonyl reductase ChKRED20 mutant in the synthesis of fused-ring lactone compounds.

[0014] The method for synthesizing a condensed-ring lactone compound by using the carbonyl reductase ChKRED20 mutant comprises the following steps: dispersing a substrate compound and the carbonyl reductase ChKRED20 mutant in a solvent and performing an enzyme-catalyzed reaction to obtain the compound.

[0015] Further, the substrate compound comprises and Any one of;

[0017] Wherein, R1 is halogen;

[0018] R2 is any one of halogen, MeO and Me;

[0019] R3 is halogen or NO2;

[0020] X is O or S.

[0021] Preferably, R1 is any one of F, Cl, Br and I;

[0022] R2 is any one of F, Cl, MeO and Me;

[0023] R3 is Br or NO2;

[0024] X is O or S.

[0025] Furthermore, the concentration of the substrate compound is 2-10 mmol / L, and the concentration of the carbonyl reductase ChKRED20 mutant is 0.5-2 mol%.

[0026] Preferably, the concentration of the substrate compound is 8 mmol / L, and the concentration of the carbonyl reductase ChKRED20 mutant is 1 mol%.

[0027] Furthermore, the solvent is a mixed solvent of PBS buffer and isopropanol, and the volume ratio of PBS buffer to isopropanol is 80-120:5-20.

[0028] Preferably, the solvent is a mixed solvent of PBS buffer and isopropanol, and the volume ratio of PBS buffer to isopropanol is 100:10.

[0029] Furthermore, the conditions of the enzyme catalytic reaction are: reaction at 35-40°C for 30-60h.

[0030] Preferably, the conditions for the enzyme-catalyzed reaction are: reaction at 37° C. for 48 hours.

[0031] The present invention has the following beneficial effects:

[0032] The present invention rationally designs ChKRED20 through directed evolution, successfully realizes the reduction reaction that the wild-type ChKRED20 and its mutant ChKRED20-M2 cannot catalyze, and the rationally designed mutant has a relatively wide substrate universality, realizes the efficient and highly selective asymmetric synthesis of large-volume condensed-ring lactones, and realizes the chirality reversal of condensed-ring lactones. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 is the chemical structure diagram of substrate 2a-17a in Example 7;

[0034] Figure 2 is the chemical structure diagram of product 2e-17e in Example 7;

[0035] Figure 3This is the liquid phase spectrum of the mutant M3C3 catalytic reduction of 1a to generate (3aR, 9bS)-1e in Example 2;

[0036] Figure 4 This is the liquid phase spectrum of the mutant M3C2 catalytic reduction of 1a to generate (3aR, 9bS)-1e in Example 3;

[0037] Figure 5 This is the liquid phase spectrum of the mutant M3C4 catalytic reduction of 1a to generate (3aR, 9bS)-1e in Example 4;

[0038] Figure 6 This is the liquid phase spectrum of the mutant M4A1 catalytic reduction of 1a to generate (3aS, 9bR)-1e in Example 5;

[0039] Figure 7 This is the liquid phase spectrum of the mutant M4B1 catalytic reduction of 1a to generate racemate 1e in Example 6;

[0040] Figure 8 This is the H NMR spectrum of the racemate 1e generated by the catalytic reduction of 1a by M4B1 in Example 6;

[0041] Fig. 9 This is the NMR carbon spectrum of the racemate 1e generated by the catalytic reduction of 1a by M4B1 in Example 6;

[0042] Fig.10 This is the liquid phase spectrum of mutant M4B1 catalytically reducing 12a to generate 12e in Example 7;

[0043] Fig.11 This is the liquid phase spectrum of the mutant M3C2 catalytic reduction of 12a to generate (3aR, 9bS)-12e in Example 7;

[0044] Fig.12 The liquid phase spectrum of the mutant M3C3 catalytic reduction of 12a to generate (3aR, 9bS)-12e in Example 7;

[0045] Fig.13 The liquid phase spectrum of the mutant M3C4 catalytic reduction of 12a to generate (3aR, 9bS)-12e in Example 7;

[0046] Fig.14 This is the liquid phase spectrum of the mutant M4A1 catalytic reduction of 12a to generate (3aS, 9bR)-12e in Example 7;

[0047] Fig.15 This is the liquid phase spectrum of the racemic isomer 12e standard;

[0048] Fig.16 This is the H NMR spectrum of the racemate 12e generated by the catalytic reduction of 12a by M4B1 in Example 7;

[0049] Fig.17 This is the NMR carbon spectrum of the racemate 12e generated by the catalytic reduction of 12a by M4B1 in Example 7. DETAILED DESCRIPTION

[0050] The principles and features of the present invention are described below in conjunction with the accompanying drawings. The examples are only used to explain the present invention and are not used to limit the scope of the present invention. If specific conditions are not specified in the embodiments, they are carried out according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0051] Example 1: Construction of carbonyl reductase ChKRED20 mutant

[0052] The construction of carbonyl reductase ChKRED20 mutants is based on the amino acid sequences of mutant strains ChKRED20-M2 (M2: Q97L / S153L, glutamine at position 97 and serine at position 153 are mutated to leucine, patent number: ZL202311261575.4) and ChKRED20-M3C1 (M3C1: Q97L / S153L / Y188S, glutamine at position 97, serine at position 153 are mutated to leucine, and amino acid at position 188 is mutated to serine, patent number: ZL202311261575.4) as starting sequences, respectively, and mutating amino acids at positions 188 and / or 145, wherein the nucleotide sequences of ChKRED20-M2 and Ch KRED20-M3C1 can be obtained from the above patents.

[0053] Among them, the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 (Q97L / S153L) was used as the starting sequence, and the tyrosine at position 188 was mutated to asparagine, and the mutant strain was named ChKRED20-M3C4;

[0054] The amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 (Q97L / S153L) was used as the starting sequence, and the tyrosine at position 188 was mutated to glycine. The mutant strain was named ChKRED20-M3C3;

[0055] The amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 (Q97L / S153L) was used as the starting sequence, and the tyrosine at position 188 was mutated to cysteine. The mutant strain was named ChKRED20-M3C2;

[0056] Using the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 (Q97L / S153L) as the starting sequence, the tyrosine at position 188 was mutated to serine, and the histidine at position 145 was mutated to alanine, and the mutant strain was named ChKRED20-M4A1;

[0057] Using the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 (Q97L / S153L) as the starting sequence, the tyrosine at position 188 was mutated to cysteine, and the histidine at position 145 was mutated to alanine. The mutant strain was named ChKRED20-M4B1.

[0058] I. Construction of mutants M3C2, M3C3, and M3C4

[0059] (1) Using ChKRED20-M2 as the DNA template sequence, PCR technology was used to perform single-point saturation mutation on tyrosine at position 188. The forward primer was 5'-gcggtggggcctgctNNKattgaaacccc-3' (SEQ ID NO.1), and the reverse primer was 5'-ggtttcaatMNNagcaggccccaccgcatt-3' (SEQ ID NO.2). PCR conditions: 95℃ pre-denaturation for 2min, 95℃ denaturation for 30s, 60℃ annealing for 30s, 72℃ extension for 6min, a total of 25 cycles, and then 72℃ extension for 10min. After the PCR was completed, 1μL of DpnI was added and digested at 37℃ for 1h. Then 10μL was transferred into 50μL of E.coli DH5α competent cells by heat shock method, and then 100 monoclonal strains were selected and sent to the company for sequencing verification, and the plasmids of M3C2, M3C3 and M3C4 were screened.

[0060] (2) After collecting the mutant library clones in step (1), extract the plasmid, transfer them into the E. coli expression strain BL21-DE3, coat them with LB plates containing kanamycin, and culture them for 12 hours. Pick a single clone in a 96-well plate, each well contains 200 μL TB medium (containing 50 μg / mL kanamycin, 0.5 mmol / L IPTG), and culture them at 30°C, 180 rpm, and shake for 18 hours. Use a 96-well plate to replicate each single clone on an LB solid medium plate, culture at 37°C for 12 hours, and then store in a refrigerator at 4°C.

[0061] (3) Preparation of pure enzyme solution: Pick the monoclonal clone obtained in step (2) into LB (containing 50 μg / mL kanamycin) medium, culture at 37°C overnight, transfer to TB (containing 50 μg / mL kanamycin) medium with a volume fraction of 1%, culture at 37°C for 3 h, add 0.5 mmol / L IPTG for induction, and continue to culture at 30°C for 18 h. Collect the bacteria by centrifugation at 4°C and 6000 rpm. Resuspend in Buffer A (50 mmol / L sodium phosphate buffer, pH 8.0, 300 mmol / L NaCl and 10 mmol / L imidazole), break the cells with a homogenizer, and then centrifuge at 13000 rpm and 4°C for 20 min. Nickel column affinity chromatography (Bio-Rad) was used for purification. The supernatant was added to the main material equilibrated with Buffer A and gently mixed for 30 minutes. The impurities were rinsed with Buffer A containing 20mmol / L imidazole, and the target protein was washed with Buffer A containing 250mmo / L imidazole. The imidazole was removed by dialyzing with sodium phosphate buffer (0.1mol / L, pH 8.0). Finally, the purity was identified by electrophoresis.

[0062] 2. Construction of mutant M4A1

[0063] (1) Using ChKRED20-M3C1 as the DNA template sequence, PCR technology was used to perform site-directed mutation of tyrosine at position 145 and mutate histidine at position 145 to alanine. The forward primer was selected as 5'-TGGCCTCTATTGCGGGTATTGTTGCTGCACCGC-3' (SEQ ID NO.3), and the reverse primer was selected as 5'-GCGGTGCAGCAACAATACCCGCAATAGAGGCCA-3' (SEQ ID NO.4). PCR conditions: 95℃ pre-denaturation for 2min, 95℃ denaturation for 30s, 60℃ annealing for 30s, 72℃ extension for 6min, a total of 25 cycles, and then 72℃ extension for 10min. After the PCR was completed, 1μL of DpnI was added and digested at 37℃ for 1h. Then 10μL was transferred into 50μL of E.coli DH5α competent cells by heat shock method, and finally 100 monoclonal strains were selected and sent to the company for sequencing verification.

[0064] (2) Collect the mutant library clones obtained in step (1), extract the plasmid, transfer them into the E. coli expression strain BL21-DE3, coat the LB plate containing kanamycin, and culture for 12 hours. Pick a single clone in a 96-well plate, each well contains 200 μL TB medium (containing 50 μg / mL kanamycin and 0.5 mmol / L IPTG), and culture for 18 hours at 30°C and 180 rpm. Use a 96-well plate to replicate each single clone on an LB solid medium plate, culture at 37°C for 12 hours, and store in a refrigerator at 4°C.

[0065] (3) Preparation of pure enzyme solution: Pick the monoclonal clone obtained in step (2) into LB (containing 50 μg / mL kanamycin) medium, culture at 37°C overnight, transfer to TB (containing 50 μg / mL kanamycin) medium with a volume fraction of 1%, culture at 37°C for 3 h, add 0.5 mmol / L IPTG for induction, and continue to culture at 30°C for 18 h. Collect the bacteria by centrifugation at 4°C and 6000 rpm. Resuspend in Buffer A (50 mmol / L sodium phosphate buffer, pH 8.0, 300 mmol / L NaCl and 10 mmol / L imidazole), break the cells with a homogenizer, and then centrifuge at 13000 rpm and 4°C for 20 min. Nickel column affinity chromatography (Bio-Rad) was used for purification. The supernatant was added to the main material equilibrated with Buffer A and gently mixed for 30 minutes. The impurities were rinsed with Buffer A containing 20mmol / L imidazole, and the target protein was washed with Buffer A containing 250mmo / L imidazole. The imidazole was removed by dialyzing with sodium phosphate buffer (0.1mol / L, pH 8.0). Finally, the purity was identified by electrophoresis.

[0066] 3. Construction of mutant M4B1

[0067] The construction method of mutant M4B1 is the same as that of mutant M4A1, except that the DNA template sequence used for M4B1 is M3C2, and the primers used are the same as those used to construct the M4A1 mutant.

[0068] Embodiment 2:

[0069] A method for synthesizing a chiral lactone compound (3aR, 9bS)-1e comprises the following steps:

[0070] The synthetic route is as follows:

[0071]

[0072] The substrate compound 1a (5 mmol / L) and the ChKRED20-M3C4 (1 mol%) obtained in Example 1 were dispersed in PBS buffer (50 mmol / L, pH = 7.9), 10% volume fraction of isopropanol was added, and then reacted at 37°C for 48 h to obtain the chiral lactone compound (3aR, 9bS)-1e.

[0073] Embodiment 3:

[0074] A method for synthesizing a chiral lactone compound comprises the following steps:

[0075] The synthesis method of the chiral lactone compound in this comparative example is the same as that in Example 2, except that ChKRED20-M3C4 is replaced by the mutant ChKRED20-M3C2.

[0076] Embodiment 4:

[0077] A method for synthesizing a chiral lactone compound comprises the following steps:

[0078] The synthesis method of the chiral lactone compound in this comparative example is the same as that in Example 2, except that ChKRED20-M3C4 is replaced by the mutant ChKRED20-M3C3.

[0079] Embodiment 5:

[0080] A method for synthesizing a chiral lactone compound (3aS, 9bR)-1e comprises the following steps:

[0081] The synthetic route is as follows:

[0082]

[0083] The substrate compound 1a (5 mmol / L) and the ChKRED20-M4A1 (1 mol%) obtained in Example 1 were dispersed in PBS buffer (50 mmol / L, pH = 7.9), 10% volume fraction of isopropanol was added, and then reacted at 37°C for 48 h to obtain the chiral lactone compound (3aR, 9bS)-1e.

[0084] Embodiment 6:

[0085] A method for synthesizing a racemic compound 1e comprises the following steps:

[0086] The synthetic route is as follows:

[0087]

[0088] The substrate compound 1a (5 mmol / L) and the ChKRED20-M4B1 (1 mol%) obtained in Example 1 were dispersed in PBS buffer (50 mmol / L, pH = 7.9), 10% volume fraction of isopropanol was added, and then reacted at 37°C for 48 hours to obtain the chiral lactone compound 1e.

[0089] Embodiment 7:

[0090] A method for synthesizing a racemic compound 2e-17e comprises the following steps:

[0091] The specific synthesis method is the same as in Example 2, using M3C2, M3C3, M3C4, M4A1 and M4B1 to synthesize substrates 2a-17a (such as Figure 1 The reaction conditions are the same as those in Example 2.

[0092] The synthesis is as Figure 2 The racemic compound shown.

[0093] Test Example 1: Test Analysis

[0094] (1) The chiral lactone compound 1e prepared in Example 2-4 was determined by high performance liquid chromatography (HPLC). HPLC conditions: OD-3 column, mobile phase: isopropanol / n-hexane volume ratio = 90 / 10, flow rate: 1 mL / min, temperature: 30° C., injection volume: 20 μL. The test results are shown in FIG. Figure 3 , Figure 4 and Figure 5 As shown, Figure 6 The standard liquid spectrum of racemate 1e, combined with Figure 3 , Figure 4 , Figure 5 and Figure 6 It can be seen that the chiral lactone compound 1e prepared using M3C2, M3C3 and M3C4 in this embodiment is a (3aR, 9bS) configuration lactone compound.

[0095] (2) The chiral value of the chiral lactone compound 1e prepared in Example 5 was measured by high performance liquid chromatography (HPLC). The test results are as follows: Figure 7 As shown, Figure 6 The standard liquid spectrum of racemate 1e, combined with Figure 6 and Figure 7 It can be seen that the chiral lactone compounds prepared using M4A1 in this example are mainly (3aS, 9bR) configuration lactone compounds.

[0096] (3) The chirality of the chiral internal compound 1e prepared in Example 4 was measured by high performance liquid chromatography (HPLC) and nuclear magnetic resonance. The experimental results are as follows: Figure 6 , Figure 8 and Fig. 9 As shown, the results showed that M4B1 produced racemate 1e.

[0097] (4) The product 12e prepared by catalytic reduction of the substrate compound 12a by M4B1, M3C2, M3C3, M3C4 and M4A1 in Example 7 was determined by high performance liquid chromatography (HPLC). The experimental results are as follows: Figure 10-Figure 14 As shown, Fig.15Comparison of the standard liquid chromatogram of the racemic compound 12e shows that M4B1 generates the racemic compound 12e, M4A1 produces the (3aS, 9bR) configuration lactone compound, and M3C2, M3C3 and M3C4 produce the (3aR, 9bS) configuration lactone compound. The NMR results of the product 12e prepared by catalytic reduction of the substrate compound 12a by M4B1 are as follows Fig.16 and Fig.17 shown.

[0098] (5) The chirality and yield of the chiral lactone compounds 1e-17e prepared from substrates 1a-17a in Examples 2-7 were detected by high performance liquid chromatography (HPLC). The results are shown in Table 1.

[0099] Table 1 HPLC specific data of 1e-17e

[0100]

[0101]

[0102]

[0103]

[0104] According to the data in the above table, the present invention rationally designed ChKRED20 through directed evolution, successfully achieved the reduction reaction that the wild-type ChKRED20 and its mutant ChKRED20-M2 could not catalyze, and achieved efficient and highly selective asymmetric synthesis of large-volume fused-ring lactones.

[0105] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A carbonyl reductase ChKRED20 mutant for the synthesis of fused-ring lactone compounds, characterized in that: Using the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 or ChKRED20-M3C1 as the starting sequence, mutating the amino acid at position 188 and / or position 145; Among them, the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 was used as the starting sequence, and the tyrosine at position 188 was mutated to asparagine; Using the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 as the starting sequence, the tyrosine at position 188 was mutated to glycine; Using the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 as the starting sequence, the tyrosine at position 188 was mutated to cysteine; Taking the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 as the starting sequence, the tyrosine at position 188 is mutated to serine, and the histidine at position 145 is mutated to alanine; or taking the amino acid sequence of ChKRED20-M3C1 as the starting sequence, the histidine at position 145 is mutated to alanine; Taking the amino acid sequence of the carbonyl reductase mutant strain ChKRED20-M2 as the starting sequence, the tyrosine at position 188 was mutated to cysteine, and the histidine at position 145 was mutated to alanine.

2. Use of the carbonyl reductase ChKRED20 mutant according to claim 1 in the synthesis of condensed-ring lactone compounds.

3. A method for synthesizing a chiral lactone compound using the carbonyl reductase ChKRED20 mutant according to claim 1, characterized in that: The method comprises the following steps: dispersing a substrate compound and a carbonyl reductase ChKRED20 mutant in a solvent to carry out an enzyme catalytic reaction to obtain the product.

4. The method for synthesizing a condensed-ring lactone compound according to claim 3, characterized in that: The substrate compound includes Any one of; Wherein, R1 is halogen; R2 is any one of halogen, MeO and Me; R3 is halogen or NO2; X is O or S.

5. The method for synthesizing a condensed-ring lactone compound according to claim 3, characterized in that: The concentration of the substrate compound is 2-10 mmol / L, and the concentration of the carbonyl reductase ChKRED20 mutant is 0.5-2 mol%.

6. The method for synthesizing a condensed-ring lactone compound according to claim 3, characterized in that: The solvent is a mixed solvent of PBS buffer and isopropanol, and the volume ratio of PBS buffer to isopropanol is 80-120:5-20.

7. The method for synthesizing a condensed-ring lactone compound according to claim 3, characterized in that: The conditions of the enzyme catalytic reaction are: reaction at 35-40°C for 30-60h.

Citation Information

Cited By

  • Method for asymmetrically synthesizing strigolactone derivative GR24 by enzyme-chemical method

    CN120174033A

  • Carbonyl reductase mutant for synthesizing chiral alcohol sulfone compound and application of carbonyl reductase mutant

    CN120400084A

  • Ketoreductase mutant and use thereof

    WO2026138986A1